Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02193828 · ClinicalTrials.gov registry record · Phase 2

Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules

A Phase 2 study of Dupuytren's Disease, sponsored by Endo Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
76
Enrollment target
11
Study locations

NCT02193828 is a Phase 2 study of Dupuytren's Disease that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 76 participants, above the 43-participant average among 4 other Dupuytren's Disease trials with a reported enrollment target (77% higher). The trial reports 11 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02193828, a Phase 2 study of Dupuytren's Disease, has completed, sponsored by Endo Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
76 participants
Enrollment target
11
Study locations

Study Summary

The objectives of this study are to assess the safety and effectiveness of AA4500 in treating palmar Dupuytren's disease nodules.

Conditions Studied

Dupuytren's Disease

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL Collagenase clostridium histolyticum

Study Locations (11)

California

  • CORE Orthopaedic Medical Center - Encinitas
  • Marin Endocrine Care & Research, Inc. - Greenbrae
  • Brigid Freyne, MD, Inc. - Murrieta

Queensland

  • Brisbane Hand & Upper Limb Clinic - Brisbane
  • Houston Medical - Kippa-Ring

Arizona

  • Tucson Orthopaedic Institute - Tucson

Indiana

  • Indiana Hand to Shoulder Center - Indianapolis

New York

  • State University of New York - Stony Brook

North Carolina

  • OrthoCarolina Research Institute, Inc. - Charlotte

Oklahoma

  • Orthopedic and Reconstructive Center - Oklahoma City

Pennsylvania

  • Blair Orthopedic Associates, Inc. - Altoona

Trial Details

FieldValue
Enrollment Target 76 participants
Start Date 2014-07
Est. Completion 2014-12
Phase Phase 2

Sponsor

Endo Pharmaceuticals

23 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02193828

The ClinicalTrials.gov registry entry for NCT02193828 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 43-participant average among 4 other Dupuytren's Disease trials with a reported enrollment target (77% higher). The listed sponsor is Endo Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dupuytren's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02193828 reports 11 study locations spanning 8 distinct geographic areas - top geographies include California, Queensland, Arizona.

Frequently Asked Questions

What is clinical trial NCT02193828 about?

NCT02193828 is a clinical study titled "Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules". The objectives of this study are to assess the safety and effectiveness of AA4500 in treating palmar Dupuytren's disease nodules.

What is the current status of trial NCT02193828?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2014-07. Estimated completion is 2014-12.

What conditions does trial NCT02193828 study?

This clinical trial studies the following conditions: Dupuytren's Disease.

What interventions are being tested in trial NCT02193828?

The interventions under investigation include: Placebo (BIOLOGICAL), Collagenase clostridium histolyticum (BIOLOGICAL).

Who is sponsoring clinical trial NCT02193828?

This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02193828 being conducted?

This trial has 11 study locations across Arizona, California, Indiana, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dupuytren's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Dupuytren's Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.